文献速递围术期管理与 ERAS急腹症与外科感染

围术期青霉素与头孢菌素过敏评估及检测:PREPARE 试点随机临床试验

Perioperative Penicillin and Cephalosporin Antibiotic Allergy Assessment and Testing: The PREPARE Pilot Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2025-01-01

这项在澳大利亚3家三级医院开展的多中心2期随机临床试验,评估了由麻醉科医生在术前门诊使用智能手机应用决策算法进行β-内酰胺类抗生素过敏评估与去标签的可行性和安全性。共纳入150例有β-内酰胺类抗生素过敏标签的成人患者,1:1随机分为干预组和对照组。结果显示干预组63.5%的患者接受了过敏检测,抗生素相关不良事件发生率为5.4%,无严重不良事件,且干预组限制性抗生素使用较少。

要点

  • 麻醉科医生在术前门诊使用决策支持算法可成功评估并去标签低风险β-内酰胺类过敏标签。
  • 干预组抗生素相关不良事件发生率5.4%,无严重不良事件,未延迟手术。
  • 干预组限制性抗生素使用比例(10.7%)低于对照组(17.9%)。

核心结论

  • 低风险β-内酰胺类抗生素过敏标签可由麻醉科医生在术前门诊成功评估并去标签。
  • 干预后无严重不良事件,表明围术期过敏去标签可不延迟手术并可能改善β-内酰胺类预防用药选择。

研究设计与样本

  • 多中心、2期可行性及安全性随机临床试验,于2020年12月14日至2023年10月31日在澳大利亚墨尔本3家三级医院的麻醉科医生主导的术前门诊开展。
  • 纳入年龄≥18岁、有报告β-内酰胺类抗生素过敏标签且围术期预防可能需静脉抗生素的成人患者,1:1随机分组。
  • 共纳入150例患者,干预组74例,对照组76例;中位年龄67岁(范围28-89岁),女性78例(52%),男性72例(48%)。

主要发现

  • 招募可行性:511例合格过敏标签患者中150例入组(29.4%;95% CI,25.4%-33.5%)。
  • 干预实施可行性:干预组74例中47例(63.5%;95% CI,51.5%-74.4%)接受了过敏检测;低风险30例中28例(93%)和中等/高风险44例中19例(43%)进行了过敏检测。
  • 安全性:干预组74例中4例(5.4%;95% CI,1.5%-13.3%)报告抗生素相关不良事件,其中1例为免疫介导(良性皮疹),无手术延迟。
  • 干预组限制性抗生素使用6例(10.7%),对照组10例(17.9%)。

关键数值与推荐

  • 风险评分指导过敏检测:低风险直接口服激发,中等至高风险先皮肤试验后口服激发。
  • 主要可行性结局为随机至干预组患者按方案接受干预的比例及同意参与患者占所有合格患者的比例。
  • 主要安全性结局为干预组术后90天内发生抗生素相关不良事件的比例。

临床怎么用

  • 麻醉科医生可在术前门诊使用智能手机应用决策支持算法对β-内酰胺类抗生素过敏标签进行评估和去标签。
  • 低风险患者可直接口服激发,中等至高风险患者需先皮肤试验后口服激发。
  • 围术期过敏去标签未导致手术延迟,且可能改善β-内酰胺类预防用药选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Antibiotic allergy labels (AALs) impact patient health and perioperative outcomes. Antibiotic allergy delabeling could improve antibiotic prescribing and infection-related outcomes perioperatively. OBJECTIVE: To assess the feasibility and safety of antibiotic allergy assessment and delabeling in anesthesiologist-led preoperative assessment clinics and expand delabeling efforts outside of specialist allergy clinics. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was a multicenter, phase 2 feasibility and safety trial conducted between December 14, 2020, and October 31, 2023, at outpatient preoperative anesthesiologist-led clinics at 3 tertiary hospitals in Melbourne, Australia. Participants were adults (age ≥18 years) with a reported β-lactam AAL likely to require intravenous antibiotic therapy for perioperative prophylaxis. Randomization was carried out on a 1:1 basis. INTERVENTIONS: Enhanced allergy assessment by anesthesiologists using a smartphone application with a decision support algorithm adapted from a validated antibiotic allergy assessment tool. Risk scores guided antibiotic allergy testing: direct oral challenge (low risk) or skin testing followed by oral challenge (medium to high risk). MAIN OUTCOMES AND MEASURES: The 2 primary feasibility outcomes were the proportion of patients randomized to intervention who received intervention per protocol and proportion of patients consenting to participate out of all eligible. The primary safety outcome was the proportion of the intervention group experiencing an antibiotic-associated adverse event (AE) within 90 days postsurgery. RESULTS: Of 150 patients enrolled, 74 were randomly assigned to receive the intervention and 76 to control. The median age was 67 years (range, 28-89 years); 78 (52%) were female and 72 (48%) were male. For feasibility of recruitment, 150 of 511 patients (29.4%; 95% CI, 25.4%-33.5%) with eligible AALs were enrolled. For feasibility of intervention delivery, 47 of 74 patients (63.5%; 95% CI, 51.5%-74.4%) randomized to intervention had allergy testing; 28 of 30 patients (93%) assessed as low risk and 19 of 44 patients (43%) assessed as moderate/high risk proceeded to allergy testing. Antibiotic-related AE were reported in 4 of 74 intervention patients (5.4%, 95% CI, 1.5%-13.3%), 1 event was immune mediated (benign rash) without a delay to surgery. There was less restricted antibiotic use in the intervention group (6 patients; 10.7%) compared with the control group (10 patients; 17.9%). CONCLUSIONS AND RELEVANCE: Low-risk β-lactam AAL were successfully evaluated and delabeled by anesthesiologists in the preoperative clinic using the intervention. The absence of severe AE after the intervention provides reassurance that antibiotic allergy delabeling can be achieved as part of a preoperative workup without delaying surgery and may improve the choice of preferred β-lactam prophylaxis. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12620001295932.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. De Luca JF, Vogrin S, Holmes NE, et al. Perioperative Penicillin and Cephalosporin Antibiotic Allergy Assessment and Testing: The PREPARE Pilot Randomized Clinical Trial. JAMA Surg. 2025. PMID: 40136281. doi:10.1001/jamasurg.2025.0279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。